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INTRODUCTION
Spinal cord injury (SCI) is a devastating illness resulting in neurological deficits and poor quality 
of life. It has an annual incidence of 15–40  cases per million and a prevalence of more than 
1 million cases in North America.[12] e incidence and prevalence of traumatic SCI is expected 
to increase as the population ages, particularly secondary to traumatic falls in the elderly.[45] e 
annual cost of SCI exceeds 7 billion dollars.[12]
is literature review focuses on the advances in pharmacology, stem cell technologies, 
neuromodulation, and external prosthetics. Several pharmacological therapies have already 
been tested in the past and are currently being investigated. Further, both neuroprotective and 
neuroregenerative drugs are being implemented in clinical trials.[45] Stem cell therapy trials are 
also ongoing, but more data are needed from Phase II clinical trials to document efficacy.
MATERIALS AND METHODS
Peer-reviewed articles were searched through PubMed using search terms “acute SCI,” “SCI 
treatment,” “neuromodulation,” “stem cell therapy for SCI,” “SCI pharmaceuticals,” and “SCI 
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exoskeleton from 1990 to 2019 (English journals). Using 
appropriate inclusion and exclusion criteria, 46 peer-reviewed 
articles were used. All studies focused on current 
advancements in the management of SCI, including stem cell 
therapies, neuromodulation, and external prosthetics.
RESULTS AND DISCUSSION
Neuroprotective and neuroregenerative pharmaceuticals 
[Tables 1and 2]
Methylprednisolone
Several neuroprotective and neuroregenerative pharmaceutical 
drugs have been investigated for SCI management. 
A  well-known neuroprotective agent, methylprednisolone, 
has been associated with improved neurological outcomes. 
It decreases the peroxidation of membrane lipids and 
posttraumatic inflammation.[45] Despite its effects in preclinical 
settings, it does still remain controversial in the clinical setting. 
A Cochrane review found no significant effect for a high-dose 
24 h infusion of methylprednisolone in terms of motor 
recovery at 6  months.[7,45] However, when started within 8 h 
after injury, an additional 4-point improvement in National 
Acute SCI Study (NASCIS) motor score was seen.[7,45] Its 
association with increased rates of gastrointestinal hemorrhage 
and wound infections also adds to its controversy.[7,45] A 
randomized controlled trial evaluating high-dose 48 h infusion 
showed no difference in NASCIS motor score recovery 
versus 24 h infusion.[6,45] e guidelines now suggest that 
methylprednisolone infusion within 8 h of injury should be 
performed only in certain situations, taking into consideration 
the associated complications.[27,45]
Naloxone, tirilazad, and nimodipine
ree drugs, naloxone, tirilazad, and nimodipine, were 
studied for their neuroprotective abilities. ey all have 
Phase III randomized controlled trials which have not 
shown any difference in NASCIS motor score recovery 
or the American Spinal Injury Association (ASIA) motor 
score between treatment and placebo groups.[5,6,27,37,45] 
Tirilazad is a nonglucocorticoid 21-aminosteroid that 
attenuates peroxidation of neuronal lipid membranes. 
Tirilazad had no difference in NASCIS motor score between 
tirilazad and 24 h infusion of methylprednisolone.[6,45] e 
neuroprotective value of naloxone is believed to be due to 
blockage of the neurotoxic effects of the endogenous opioid 
dynorphin A. Nimodipine is a calcium channel blocker 
that inhibits calcium-dependent activation of lytic cellular 
enzymes as well as presynaptic glutamate release.[5,37,45]
Riluzole
Riluzole, a sodium channel blocker approved for the 
treatment of amyotrophic lateral sclerosis, has been studied in 
preclinical models of SCI. It diminishes secondary injury by 
blocking activation of sodium channels and reducing release 
of neuronal glutamate.[41,45] Phase I/II trials evaluating the 
Table 1: Neuroprotective pharmaceuticals.
Drug Mechanism Evidence on efficacy
IV Methylprednisolone[6,7,45] Neuroprotection through reduction 
of membrane lipids peroxidation and 
posttraumatic inflammation
Limited evidence on neuroprotective properties, 
most recent studies failed to prove real benefit as 
treatment in acute SCI
Naloxone[5,37,45] Inhibition of neurotoxic effect of endogenous 
opioid dynorphin A
No evidence of improvement in NASCIS or ASIA 
motor scores
Tirilazad[5,37,45] Decreases peroxidation of lipid neuronal 
membranes
No evidence of improvement in NASCIS or ASIA 
motor scores
No difference in NASCIS motor score when 
compared to 24 h infusion of methylprednisolone
Nimodipine[5,37,45] Calcium channel blocker that prevents 
calcium-dependent activation of apoptotic 
enzymes and blocks release of presynaptic 
glutamate
No evidence of improvement in NASCIS or ASIA 
motor scores
Riluzole[14,22,45] Sodium channel blocker, reduces sodium-
dependent glutamate release diminishing 
neuronal injury
Phase I trials have shown a gain of 15.5 in motor 
score. Phase IIB and III trials are ongoing
Minocycline[8,15,28,45] Modified form of tetracycline (antibiotic), 
reduces inflammation, neuronal apoptosis, and 
microglial activation
Phase II trials have shown improvement in motor 
score (14 points). Phase III trials are ongoing
Basic fibroblast growth factors[45,44] Neuroprotection by reducing glutamate-
mediated excitotoxicity
Pending results from Phase I/II clinical trials
ASIA: American Spinal Injury Association, NASCIS: National Acute Spinal Cord Injury Study
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safety and pharmacokinetics of riluzole began in humans in 
2010 and were completed in 2012.[14,22,45] In the Phase I trial, 
a gain of 15.5 points in motor score for patients with cervical 
injuries was found for the riluzole group of 24 patients over 
the comparison registry group of 26 patients.[22] At 180 days, 
there was a gain of 31.2 points for patients with cervical 
injuries for 24 riluzole patients and of 15.7 points for 26 
registry patients.[22] ere was a gain of 9 points in pinprick 
scores in riluzole patients with complete or incomplete 
cervical injuries versus registry patients.[22] A Phase IIB/III 
double-blinded randomized controlled trial was started in 
2014 looking at the safety and neuroprotective efficacy of 
riluzole in patients with acute cervical SCI. ese results will 
provide Class I evidence regarding the use of riluzole.
Minocycline
Minocycline, a modified form of tetracycline, is another 
neuroprotective agent that has shown some promise 
in animal models.[15,45] In animal models of SCI, it has 
been shown that minocycline decreases neuronal and 
oligodendrocytes apoptosis, microglial activation in addition 
to anti-inflammatory effects.[15] In randomized controlled 
Phase II clinical trials, minocycline was associated with 
14-point gain in motor score over placebo in patients with 
cervical SCI.[8,22,45] Pinprick scores in these motor-incomplete 
patients were 14 points higher than placebo.[22,28,45] 
Phase III clinical trials will be able to provide further 
evidence regarding its use.
Fibroblast growth factor
Basic fibroblast growth factor has shown to provide 
neuroprotection by improving functional and respiratory 
parameters in animal models by reducing glutamate-mediated 
excitotoxicity.[44,45] ere are current Phase I/II trials that are 
further investigating this therapy. Furthermore, cytokine 
granulocyte colony-stimulating factor which inhibits tumor 
necrosis factor-alpha and interleukin-1 beta, promoting cell 
survival has shown benefits in two nonrandomized studies.[31,43]
GM-1 ganglioside (Sygen)
A neuroregenerative agent, GM-1 ganglioside (Sygen) has 
been shown to enhance axonal regeneration in laboratory 
studies.[45] Gangliosides are important glycolipid molecules 
that are components of neuronal membranes. Randomized 
placebo-controlled trial using this agent did not show any 
difference in neurological recovery in patients at 6 months.[16,45]
Cethrin
Cethrin is a permeable paste that can be applied to spinal cord 
dura postinjury that is a combination of a bacterial-derived 
toxin, BA-210, and a biohemostatic adhesive. It inhibits the 
Rho pathway of inhibitory proteins and promotes axonal 
growth in vitro.[45] Phase I/IIa trials were done where it was 
applied to dura in patients with complete injuries, and no 
complications were seen at 1-year follow-up.[13,45] In fact, in 
patients with cervical injuries receiving cethrin, there was an 
improvement in ASIA motor score.[45]
Anti-Nogo
Another neuroregenerative drug, anti-Nogo, is a monoclonal 
antibody made to bind to Nogo-A, and has been shown to 
promote neural regeneration.[45] Nogo-A is a protein that 
blocks axonal growth in the central nervous system.[45] is 
anti-Nogo agent is still under investigation. Many of these 
neuroprotective and neuroregenerative agents have shown 
promising results and future studies will be helpful in 
establishing their efficacy.
Neuromodulation [Table 3]
It is well known that neuromodulation, the use of 
electrical stimulation to alter neuronal circuitry, has 
Table 2: Neuroregenerative pharmaceuticals.
Drug Mechanism Evidence on efficacy
G-CSF[31,43] Inhibition of TNF-alpha and IL-1 beta, promoting cell 
survival
Phase I/IIa clinical trials have shown 
improvement in ASIA motor score (P<0.01)
GM-1 ganglioside (Sygen)[16] Component of neuronal membranes enhances axonal 
regeneration in laboratory studies
Randomized placebo-controlled trial did 
not show benefits
Cethrin[13,45] Bacterial-derived toxin, BA-210, and a biohemostatic 
adhesive inhibit the Rho pathway of inhibitory proteins 
and promotes axonal growth
Benefits shown in Phase I/IIa trials. 
Improvement in AISA motor score
Anti-Nogo[45] Monoclonal antibody binds and inhibits Nogo (protein 
that blocks axonal growth in the CNS through activation 
of Rho pathway), promoting neuronal regeneration
Currently in early phase clinical trials
CNS: Central nervous system, G-CSF: Granulocyte colony-stimulating factor, ASIA: American Spinal Injury Association, TNF: Tumor necrosis factor, 
IL: Interleukin
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been tried in various neurological disorders including 
SCI. Neuroplasticity-mediated functional recruitment of 
axons (particularly spared axons) to potentiate sprouting, 
regeneration, and formation of new interconnections 
between neurons forms the basis of modern 
neuromodulation techniques. is is complemented with the 
presence of some intact ascending and descending circuits 
in patients with SCI, making neuromodulation a feasible 
option.[29] Spinal cord stimulation, one of the forms of 
neuromodulation, is a rapidly growing method for SCI. For 
spinal cord stimulation, epidural or transcutaneous method 
may be used, and clinical studies have already demonstrated 
some improvement in motor function with these methods.
[3,20,23] Besides, spinal cord stimulation techniques, brain 
stimulation, and peripheral nerve stimulation are other 
approaches to neuromodulation in SCI.[29] Several studies 
have demonstrated functional improvement in volitional 
movements of lower limbs and hand dexterity in patients 
with SCI.[3,17] However, whether neuromodulation is 
affordable and accessible to all patients remains a major 
challenge.[29]
Activity-dependent plasticity
Moreover, the concept of activity-dependent plasticity has 
been recently employed to achieve substantial improvements 
in motor function, based on the recent finding that 
neurorehabilitation is the only treatment option which can 
be offered to SCI patients for long-term improvement in 
motor function.[26] In this model, high-intensity training 
combined with electrical neuromodulation has shown to 
improve neuronal connections and circuits within the spinal 
cord by working synergistically at least in a subpopulation of 
patients.[26] is holds great promise for recovery of motor 
function after SCI.
Spinal cord stimulation
With respect to spinal cord stimulation, epidural spinal 
stimulation has well been tested in patients with chronic pain 
and most recently in patients with SCI. is method involves 
surgical placement of electrodes onto the dorsal surface of the 
spinal cord.[29] Several studies utilizing neuromodulation in 
patients with SCI ASIA A and B demonstrated an improved 
ability to make lower extremity voluntary movements 
following epidural stimulation of their spinal cord.[3,20,23] 
Moreover, with respect to the effects on upper body, one case 
study demonstrated improvements in handgrip strength and 
motor strength of the upper extremities in patients following 
epidural spinal stimulation once a day.[34] Unlike the epidural 
method, transcutaneous stimulation is another method 
and is a noninvasive approach to spinal cord stimulation. It 
involves placement of electrodes onto the skin surface of a 
patient. Aside from experimental studies on animals, more 
clinical trials and studies are needed to fully ascertain the 
advantages as well as long-term side effects of spinal cord 
stimulation for SCI.[29]
Brain stimulation for SCI
Brain stimulation for SCI is also currently being employed. 
Transcranial direct current stimulation and transcranial 
magnetic stimulation are two main approaches that are being 
used to augment the neuronal plasticity between the spinal 
cord and the brain in individuals with SCI.[29] Several studies 
have already demonstrated to improve functional outcomes 
from using transcranial direct current stimulation in patients 
with motor complete SCI.[17,36,38] Transcranial direct current 
stimulation is a noninvasive method to deliver direct current 
with the use of scalp electrodes.[17] Transcranial magnetic 
stimulation is another noninvasive approach that delivers 
Table 3: Other modalities; neuromodulation, stem-cell transplant, and prosthetic devices.
Modality Mechanism Evidence on efficacy
Neuromodulation
Spinal cord stimulation (epidural and  
transcutaneous)[3,20,23,29]
Brain stimulation (transcranial direct current 
stimulation and transcranial magnetic  
stimulation)[1,4,11,17,25,36,38]
Improves neuronal connections 
and circuits within the spinal cord 
in the remaining intact tracts
Some benefits and improved functional 
outcomes shown in several studies
Stem cell-based therapies[10,30,33,39,40,42,46] Precursors for neuronal 
regeneration. Oligodendrocyte-
induced remyelination, axonal 
elongation, and tract regeneration
Phase I clinical trials showed promising 
results, however, phase II/III trials, and 
ethical and legal concerns are still need 
to be addressed
Prosthetic devices[9,19,21,35] Providing physical assistance, 
restoration of a certain level of 
physical activity, and improvement 
in cardiovascular health and gait 
parameters
Several studies showed improvement in 
functional outcomes and restoration of 
certain level of physical activity
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magnetic waves to the brain and has shown improvements 
in hand function in studies on patients with tetraplegia. Fine 
motor tasks and handgrip strength improved with the use of 
transcranial magnetic stimulation.[2,18] Transcranial magnetic 
stimulation can also have a positive impact on patient’s 
walking speed as evidenced by one of the trials.[32] Larger 
scale trials are needed to assess these promising results. In 
addition, although deep brain stimulation has already been 
tested in experimental studies on animals, its potential in 
treating patients with SCI still needs to be elucidated with 
clinical trials and further research.[24]
Brain–machine interfaces
Brain–machine interfaces are another modern tool for 
patients with SCI. ese devices, which can be used to 
control various prosthetic devices such as the exoskeleton 
as well as directly stimulate paralyzed muscles, have already 
demonstrated improved outcomes in patients with SCI 
through several recent studies.[1,4,11,25] Clinical trials for 
the use of brain–machine interfaces and their computer 
algorithms are ever increasing as further research into 
advances in technology, feasibility and accessibility of these 
devices are still needed. In conclusion, due to increasing 
promising results, neuromodulation for SCI will remain a 
rapidly growing field in the upcoming years.
Stem cell-based therapies [Table 3]
Stem cell-based therapies and cellular scaffolds have yielded 
promising progress with respect to neuronal repair.[10] 
Phase I clinical trials have demonstrated that transplantation 
of olfactory ensheathing cells can be a safe, promising 
option to aid in neuronal repair in patients with SCI, but 
more Phase II clinical trials are still needed.[33,42] Several 
trials have also demonstrated the safe use of transplanted 
neuroprotective Schwann cells for nerve repair in patients 
with SCI, but clinical trials assessing the actual efficacy of this 
method are still ongoing.[39,40,46] In addition, several clinical 
trials have also demonstrated safety in using stem cells 
from various sources for SCI, but there are many more that 
are in the process of recruiting patients for transplantation 
of various stem cells.[10] Ethical and tumorigenesis concerns 
with stem cell-based therapies, however, will certainly need 
to be addressed as their research evolves.[10]
In vitro manipulation of the embryonic stem cells (ESCs)
Recently, in vitro manipulation of the ESCs differentiation 
to neuronal and glial lineages under controlled conditions 
has shown promising results after transplantation in animal 
models of acute SCI.[30] ese included oligodendrocyte-
induced remyelination, axonal elongation, and tract 
regeneration. However, legal and ethical drawbacks have 
limited the employment of ESC in the treatment of SCI 
patients. is might be largely attributed to the destruction 
of the blastocyst on isolation of the cells.[30] Moreover, 
development of teratomas after ESCs transplantation in 
numerous animal models has raised significant concerns 
about the functionality of these cells as a potential therapeutic 
avenue in SCI management.[30]
Various cell-based therapies
Despite extensive research exploring various cell-based 
therapies such as transplantation of oligodendrocyte precursors, 
induced pluripotent stem cells, bone marrow-derived 
(BM-MSCs), adipose-derived (AD-MSCs), and umbilical cord 
(U-MSCs),[30] there have been a lack of large Phase III clinical 
trials investigating the therapeutic efficacy of stem cell therapy.
Prosthetic devices [Table 3]
Robotic exoskeletons or powered exoskeletons have emerged 
as an advantageous rehabilitation tool for certain disabled 
individuals with SCI. e studies provided preliminary 
evidence on efficacy of exoskeletons on cardiovascular health, 
energy expenditure, body composition, gait parameters, level 
of physical activity, neuropathic pain level, and quality of life. 
ey can be used to restore a certain level of physical activity 
years after injury.[9,19,35] Body weight supported treadmill 
training and locomotion training with driven gait orthosis 
are now considered essential component in the rehabilitation 
of SCI patients. According to the meta-analysis of powered 
exoskeletons, <5% of SCI patients have the ability to ambulate 
without any physical assistance.[35] However, following an 
exoskeleton training program, 67% of patients were able to 
walk with exoskeleton-assisted ambulation without physical 
assistance.[35] is meta-analysis included exoskeletons such 
as ReWalkTM, EksoTM, and IndegoTM. In addition, even in 
complex training situations, there were no adverse events, falls, 
or fractures.[35] Furthermore, the neurologically controlled 
exoskeleton HALTM has recently been Food and Drug 
Administration approved for use in the United States. is 
system has been proven to be beneficial in the rehabilitation of 
patients with chronic spinal cord injuries.[21] is technology 
is constantly being evolved, and it is important to strive 
for an interdisciplinary team approach to provide greater 
accessibility to this technology. is might help patients to 
preserve the physical capacity before restoration becomes 
necessary. e future of prosthetic devices is bright for SCI 
patients and will continue to be investigated.
CONCLUSION
We investigated the advancements in neuroprotective 
pharmacology, stem cell technologies, neuromodulation, 
and various external prosthetics for the treatment of SCI. 
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However, more clinical trials and research will continue to 
establish their efficacy.
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